{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:31Z","timestamp":1793176771267,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T22:32:03Z","timestamp":1704493923000},"page":"491-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5012-7312","authenticated-orcid":false,"given":"Ziv","family":"Savin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-0211","authenticated-orcid":false,"given":"Roy","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Lazarovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barak","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reut","family":"Shashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4035-2935","authenticated-orcid":false,"given":"Azik","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Pilosov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Freifeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagi Arieh","family":"Shpitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-5820","authenticated-orcid":false,"given":"Shay","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Yossepowitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Sofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clgc.2024.01.004_bib0001","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2024.01.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222223","article-title":"Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: a meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.004_bib0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000321008","article-title":"Preoperative hydronephrosis predicts advanced bladder cancer but is not an independent factor for cancer-specific survival after radical cystectomy","volume":"86","author":"Hofner","year":"2011","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.004_bib0004","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/JU.0000000000001548","article-title":"Does Ureteral stenting increase the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors? A systematic review and meta-analysis","volume":"205","author":"Sountoulides","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.004_bib0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12885-020-6620-2","article-title":"Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer","volume":"20","author":"Hupe","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.004_bib0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-2006-948768","article-title":"Emergency percutaneous nephrostomy","volume":"23","author":"Regalado","year":"2006","journal-title":"Semin Intervent Radiol"},{"issue":"11","key":"10.1016\/j.clgc.2024.01.004_bib0007","first-page":"5581","article-title":"Long-term follow-up results and complications in cancer patients with persistent nephrostomy due to malignant ureteral obstruction","volume":"28","author":"Alma","year":"2020","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.004_bib0008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.004_bib0009","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.euf.2017.02.014","article-title":"Validation of the Clavien\u2013Dindo grading system in urology by the European Association of Urology Guidelines Ad Hoc Panel","volume":"4","author":"D","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"5b","key":"10.1016\/j.clgc.2024.01.004_bib0010","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/bju.12274","article-title":"Eligibility for neoadjuvant\/adjuvant cisplatin-based chemotherapy among radical cystectomy patients","volume":"113","author":"Thompson","year":"2014","journal-title":"BJU Int"},{"issue":"9","key":"10.1016\/j.clgc.2024.01.004_bib0011","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.004_bib0012","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.004_bib0013","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"33","key":"10.1016\/j.clgc.2024.01.004_bib0014","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II\u2013results of EORTC study 30986","volume":"27","author":"De Santis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.004_bib0015","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.euo.2018.07.009","article-title":"Discerning patterns and quality of neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer","volume":"2","author":"Huo","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2024.01.004_bib0016","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.urolonc.2019.04.006","article-title":"Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer","volume":"37","author":"Macleod","year":"2019","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:26:40Z","timestamp":1793176000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767324000041"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}